Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study

Abstract Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors offer cardiovascular benefits in patients with heart failure, yet their direct effects on myocardial fibrosis—particularly in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D)—remain underexplored....

Full description

Saved in:

Bibliographic Details
Main Authors:	Arif Albulushi, Kimia M. Askari, Ammar M. Al-Abedi, Malak A. Al-Kulaibi, Murtadha S. Hasan, Zahra Hosseini, Mezon T. Al-Rahman, Desmond B. Tanoh, Amjad S. Hasan, Yaseen Al-Helli, Ahmed Basouni
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Series:	European Journal of Medical Research
Subjects:	HFpEF Myocardial fibrosis Dapagliflozin SGLT2 inhibitors Type 2 diabetes Cardiac MRI
Online Access:	https://doi.org/10.1186/s40001-025-02834-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
by: Lingyun Luo, et al.
Published: (2025-04-01)

Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning
by: Muyashaer Abudurexiti, et al.
Published: (2025-04-01)

Sex‐related pathophysiological mechanisms may be present before symptoms of HFpEF develop
by: B. Wong, et al.
Published: (2025-06-01)

Cardiometabolic Phenotype in HFpEF: Insights from Murine Models
by: Ekaterina Ogurtsova, et al.
Published: (2025-03-01)

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients
by: Michał Czapla, et al.
Published: (2025-08-01)

Specific targeting of adipose tissue metabolism is superior to caloric restriction in treating obesity-related HFpEF
by: Simon Sedej, et al.
Published: (2025-07-01)

Schaftoside improves HFpEF through regulation the autophagy-lysosome pathway by allosterically targeting CaMKII-δ
by: Haiying Zhang, et al.
Published: (2024-12-01)

Hepatocyte growth factor and B-type natriuretic peptide as independent predictors of mortality in HFpEF patients
by: Hou-liang Chen, et al.
Published: (2025-02-01)

Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF
by: Zhen-Yu Yang, et al.
Published: (2025-08-01)

Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies
by: Francesca Coppi, et al.
Published: (2025-06-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study
by: Weilun Meng, et al.
Published: (2025-02-01)

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis
by: Mingzhi Lin, et al.
Published: (2025-05-01)

Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF
by: Katherine L. Dominic, et al.
Published: (2024-12-01)

MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction‐Regulating Proteins in a Rat Model of HFpEF
by: Beatrice Vahle, et al.
Published: (2025-06-01)

Targeting atrial fibrillation in HFpEF: the emerging role of pulsed field ablation
by: A. S. Parwani, et al.
Published: (2025-07-01)

Ventricular interdependent phenotype of mixed Cpc‐pulmonary hypertension and HFpEF with normal left atrium: Impact on CPET metrics and clinical outcomes
by: Giovanna Zampierollo‐Jaramillo, et al.
Published: (2024-10-01)

Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF
by: Patrick A. Kwaah, MBChB, et al.
Published: (2025-07-01)

Microvascular dysfunction across organs in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study
by: Jerremy Weerts, et al.
Published: (2025-07-01)

Type 2 diabetes worsens the outcome of ischemia/reperfusion in female STEMI patients and female db/db mice with HFpEF cardiometabolic phenotype
by: Ivana Iveljic, et al.
Published: (2025-06-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Atrial dysfunction: a contrast-free marker for HFpEF in obese diabetics—insights from comprehensive CMR and serum biomarker analyses
by: Rebecca Elisabeth Beyer, et al.
Published: (2025-06-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Heart failure with preserved ejection fraction (HFpEF): phenotypes, diagnostic algorithms, and new therapeutic options
by: Arnold Péter Ráduly, et al.
Published: (2025-02-01)

Targeted Overexpression of Mitochondrial ALDH2 in Coronary Endothelial Cells Mitigates HFpEF in a Diabetic Mouse Model
by: Guodong Pan, et al.
Published: (2025-07-01)

Clinical profile of heart failure in geriatric patients in a tertiary cardiac hospital of Bangladesh
by: Mahbuba Yesmin, et al.
Published: (2025-06-01)

Single nuclei RNA-sequencing unveils alveolar macrophages as drivers of endothelial damage in obese HFpEF-related pulmonary hypertension
by: Era Gorica, et al.
Published: (2025-07-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01)

The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
by: Francesca Cinti, et al.
Published: (2025-05-01)

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment
by: Era Gorica, et al.
Published: (2025-07-01)

Impact of Voluntary Exercise on Systemic Inflammation in a 2‐Hit Model of Heart Failure With Preserved Ejection Fraction
by: Heather Quiriarte, et al.
Published: (2025-02-01)

Cardiopulmonary exercise testing as a prognosis‐assessing tool in heart failure with preserved ejection fraction
by: C. Rozados daConceicao, et al.
Published: (2025-06-01)

Exploring the Noninvasive Evaluation of the Pulmonary Pressure–Flow Relationship During Exercise
by: Mads J. Andersen, et al.
Published: (2024-08-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
by: Mark Sweeney, et al.
Published: (2020-09-01)

Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors
by: Akshat Agrawal, et al.
Published: (2025-07-01)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
by: Shuo Xu, et al.
Published: (2025-04-01)

Multiparity induces persistent myocardial structural, functional and transcriptomic remodelling in mice
by: Ruth R. Magaye, et al.
Published: (2025-07-01)

Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction
by: Sher May Ng, et al.
Published: (2025-10-01)